MARKET

IMVT

IMVT

Immunovant Inc
NASDAQ
39.71
-1.38
-3.36%
After Hours: 39.54 -0.17 -0.43% 17:20 07/10 EDT
OPEN
41.10
PREV CLOSE
41.09
HIGH
41.10
LOW
39.40
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
41.23
52 WEEK LOW
14.32
MARKET CAP
8.15B
P/E (TTM)
-14.3275
1D
5D
1M
3M
1Y
5Y
1D
Larimar, Cytokinetics, Itau, Global-e, Immunovant Shake-Up
TipRanks · 1d ago
Top Immunovant Executives Quietly Cash Out in Major Insider Stock Move
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT), Ionis Pharmaceuticals (IONS) and Gilead Sciences (GILD)
TipRanks · 3d ago
Immunovant CEO Eric Venker disposes of common shares worth $3.46 million
PUBT · 6d ago
Weekly Report: what happened at IMVT last week (0629-0703)?
Weekly Report · 6d ago
Chief Technology Officer Of Immunovant Sold 53% Of Their Shares
Simply Wall St · 07/02 15:48
Immunovant Is Maintained at Buy by Citigroup
Dow Jones · 06/30 18:59
Immunovant Price Target Raised to $61.00/Share From $57.00 by Citigroup
Dow Jones · 06/30 18:59
More
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).

Webull offers Immunovant Inc stock information, including NASDAQ: IMVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMVT stock methods without spending real money on the virtual paper trading platform.